Cerdelga eliglustat tartrate regulatory update

Sanofi’s Genzyme Corp. unit said Japan approved Cerdelga eliglustat to treat Type I Gaucher’s disease in adults. The ceramide analog that inhibits glucosylceramide synthase (GCS) is approved in the ...